Will the implementation of high-priced HPV vaccines be completely reduced to "chicken ribs" for free vaccination?

text

A few days ago, the Chongqing Municipal Health Commission held a teleconference on the city's health work in 2022, and deployed key tasks for 2022

It mentioned that in 2022, Chongqing will start the free vaccination of school-age girls against cervical cancer

According to statistics, more than 80% of women have at least one HPV infection in their lifetime

The HPV vaccine has become a "type of vaccine", can it still attract gold?

In developed countries such as the United States, the HPV vaccine has basically achieved "free vaccination for all", and with the increasing calls for free HPV vaccination in China, in the past two years, many places have gradually started HPV vaccine pilot vaccination

The public only needs to pay the vaccination service fee, and then the vaccination can be implemented in the local designated medical institutions

It is precisely because of this that after learning that the government is free to receive HPV vaccines, many people think about whether related companies are expected to benefit

But is HPV vaccine free vaccination really a good thing for related pharmaceutical companies?

From self-funded to public funds, with the continuous promotion of free HPV vaccination by local governments, it means that women aged 13-15 are almost unprofitable for enterprises.

Can HPV, the money printing machine, still attract gold like it does now?

HPV's short-term "rich-making" effect continues

Of course, no matter how the free vaccination of HPV vaccine develops, it is a matter of the future, at least for now, the richness of HPV vaccine is still going on

According to relevant data, there are four main types of HPV vaccines approved for marketing in China, namely the bivalent vaccine of Wantai Bio, the bivalent vaccine of GSK, and the quadrivalent and ninevalent vaccines of Merck &

It is generally believed that the higher the price of the HPV vaccine, the more types of viruses it protects, and the higher the corresponding price

In terms of price, the domestic vaccine Wantai Bio’s Xinkening has the most obvious advantage.

Recently, major HPV manufacturers have announced their respective business income.

The HPV vaccine batch release data in 2021 has greatly highlighted the gradually dominant position of Wantai Bio's bivalent vaccine in the domestic market, and due to the harsh admission conditions of the HPV vaccine itself, most companies are greedy but unable to do so.

In addition, the supply of products in the entire market is in short supply, and the competition in the industry is not fierce.

High-priced HPV vaccine may become a chicken rib

But it is worth noting that, on the one hand, with the capital market's injection of HPV vaccines, and after Wantai's biological Zhong Suisui became the richest man in China with 2-valent HPV, the overall status of HPV vaccines has risen, whether it is 2, 4, or 9 prices.

At present, in the field of bivalent vaccines, in addition to Wantai Bio, Shanghai Zerun has made the fastest progress in the layout of HPV vaccines.

However, in addition to the above layout, some domestic players have set their sights on higher-priced HPV vaccine products in order to cope with the competition
.
For example, the 11-valent HPV vaccine developed by China Biotechnology Institute has entered the clinical phase 2, and the 16-valent HPV vaccine being developed by Zhejiang Pukang is also in the clinical phase 1
.

However, although the market generally believes that the trend of replacing low prices with high HPV prices will be a long-term trend in the future, in the current stage of HPV vaccine layout, blindly pursuing high prices is not necessarily a wise move, at least from the perspective of market feedback.
It is not that the higher the price, the more money can be earned, and the protection rate (the infection rate caused by human papilloma virus) brought by the increase in the price has not been greatly improved.
On the contrary, due to the increase in cost and difficulty, the current free vaccination is lost.
opportunity
.

At the same time, for now, experts still do not recommend women who have been vaccinated with the 2-valent HPV vaccine, and then continue to receive the higher-priced HPV vaccine, so at least for now, if the government's free HPV vaccination program continues to be implemented, such as 11-valent HPV vaccine, 16-valent HPV vaccine In the future, high-priced vaccines such as these will lose most of the market, and even become completely useless after a few decades
.